PHILADELPHIA (AP) — A U.S. health panel says it’s time to resume use of Johnson & Johnson’s COVID-19 vaccine, despite a very rare risk of blood clots. Out of nearly 8 million people vaccinated before the U.S. suspended J&J’s shot, health officials uncovered 15 cases of a highly unusual kind of blood clot, three of them fatal.
All were women, most younger than 50.READ MORE: Police: Body Found In Ocean Off New Jersey Identified As Man Missing For 4 Days
But advisers to the Centers for Disease Control and Prevention said Friday the vaccine’s benefits outweigh that serious but small risk — especially against a virus that’s still infecting tens of thousands of Americans every day.READ MORE: CBS3 Pet Project: As Halloween Approaches, Remember Not All Dogs Will Enjoy Wearing Costumes
The government will rapidly weigh that recommendation in deciding next steps.MORE NEWS: AIDS Walk Philly, Region's Largest HIV Awareness Event, Underway At Art Museum
(Copyright 2021 by The Associated Press. All Rights Reserved.)